Phase II study of olaparib plus durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC) - Drew, Y; Kaufman, B; Banerjee, S (Ann Oncol, 2019)